Introduction
The incidence of renal cell carcinoma (kidney cancer) has been increasing worldwide, with more than 300 000 new cases now diagnosed annually [1] . This rising incidence is probably due in part to the widespread use and increasing sensitivity of abdominal imaging. The detection of small renal masses has caused a stage migration for patients diagnosed with kidney cancer such that the majority of patients are diagnosed with localized disease, which has a 5-yr survival of >90%. In addition, small renal masses and kidney cancers are often diagnosed in the sixth decade of life, when competing risks of mortality are common. While more kidney cancers are being detected and treated, survival among patients with kidney cancer has not improved as dramatically [1] .
For these reasons, there is a need to increase awareness of the potential overdiagnosis and overtreatment of patients diagnosed with kidney cancer. Overdiagnosis refers to the detection of a small renal mass that would not go on to cause symptoms or death [2] . Similarly, overtreatment refers to the removal of a benign renal mass or a kidney cancer that would either never progress or progress "slowly enough that the patient would die of other causes before the cancer becomes symptomatic" [2] . A patient diagnosed with a renal mass can be exposed to many harms (Fig. 1 ). 
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Harms of overdiagnosis
Abdominal imaging has the ability to incidentally detect small, asymptomatic renal masses. As current imaging techniques are unable to definitively distinguish benign tumors, many patients receive a diagnosis of kidney cancer based solely on the detection of a small renal mass. This can subsequently cause psychological stress stemming not only from concern about survival, but also from uncertainty and changes in identity. In a recent study, 27% of patients undergoing treatment for kidney cancer were found to require psychosocial care [3] . Even patients with early-stage kidney cancer described anxiety, pain, sadness, and difficulty in sleeping [3] . Furthermore, a cancer diagnosis often leads patients to seek additional medical care, may adversely alter patients' financial and social planning, and can increase the odds of suicide [3] . The understanding of the impact of a cancer diagnosis and its potential to lead to unnecessary testing has increased calls to restrain the use of unnecessary imaging studies [4] .
Underutilization of active surveillance
The detection of a small renal mass often leads to surgical treatment. In the USA, regional rates of abdominal imaging are strongly associated with the rates of kidney surgery [5] . Sadly, as many as one-third of patients treated with partial nephrectomy discover that they underwent surgery to remove a benign lesion [6] . The diffusion of robotic kidney surgery appears to be associated with increasing surgical treatment of small renal masses, which is outpacing active surveillance even among elderly patients [7] . Prospective data show that active surveillance of small renal masses is associated with 100% 5-yr cancer-specific survival [8] . Moreover, initial active surveillance can also help in identifying tumors with worrisome growth and in guiding selection for definitive treatment. Clearly, active surveillance-the ultimate nephron-sparing approach-remains underutilized [9] .
Underutilization of renal mass biopsy
While renal mass biopsy has the potential to provide histological confirmation of cancer, it is underutilized. From 1992 to 2007, only one in five patients undergoing radical or partial nephrectomy underwent renal mass biopsy before surgery, although rates of biopsy are slowly increasing [10] . With current techniques, renal mass biopsy is safe and has a diagnostic accuracy of >90%. However, routine renal mass biopsy may not be appropriate for all patients with a small renal mass. Renal mass biopsy remains limited in its ability to reliably determine tumor grade. In addition, efforts are needed to determine when treatment can be avoided in healthy patients with long life expectancy. Moreover, a renal mass biopsy itself may represent overtreatment in older frail patients, for whom active surveillance might be the default management regardless of histologic confirmation of renal cell carcinoma.
Harms of overtreatment: surgical complications
While operative complications are the most obvious danger resulting from overtreatment of small renal masses with surgery, complications associated with partial and radical nephrectomy have decreased over time [11] . However, while most patients tolerate kidney surgery well, the risks of kidney surgery include blood transfusion (5% of minimally invasive surgeries, and up to 20% of open surgeries), reoperation (2-5%), prolonged ventilation and respiratory complications (1-7%), and even death [11] . The 90-d mortality rate following partial or radical nephrectomy has been reported to be as high as 4.3% [5] . For older or comorbid patients, the risks of surgery may significantly outweigh the risks of undertreatment of a small renal cell carcinoma.
Renal morbidity following kidney cancer surgery
In addition to surgical complications, the long-term health effects of a decrease in kidney function after kidney surgery remain an ongoing issue. Small changes in kidney function have been associated with significant adverse health outcomes, such as cardiovascular events, hospitalization, and death. While the benefits of preserving kidney function remain unclear, partial nephrectomy has become a standard surgical approach for preserving renal parenchyma and kidney function. However, patients who undergo partial nephrectomy are typically younger and healthier [12] . This suggests that the patients most vulnerable to renal insult are being left out.
Strategies to minimize overdiagnosis and overtreatment
Until there is a proven screening test for kidney cancer, efforts to minimize the harms of overdiagnosis and overtreatment will require patient-centered approaches (Fig. 2) . Curbing inappropriate abdominal imaging studies may limit the overdiagnosis of asymptomatic small renal masses. Overtreatment can be minimized by encouraging the use of active surveillance for patients with limited life expectancy and multimorbidity. Renal mass biopsy can also help in riskstratifying patients and in guiding treatment selection. Finally, ongoing research efforts to develop biomarkers that can personalize care for kidney cancer patients will be critical.
Conclusions
The harms resulting from both overdiagnosis and overtreatment are diverse, and there is now a greater onus on clinicians to both recognize these risks and to appropriately counsel patients. Shared decision-making and better patient selection tools will ultimately help in guiding treatment selection and in minimizing the morbidity in patients diagnosed with a small renal mass.
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